Business Description
3D Medicines Inc. is a China-based company founded in 2014 and headquartered in Qingdao, focused on creating and bringing to market treatments for various types of cancer. Its lead product, Envafolimab, is an injectable therapy already approved for certain advanced solid tumors and currently being tested in multiple late-stage clinical trials for additional cancer types. The company also has a broad pipeline of over ten other drug candidates at various stages of development, targeting cancers ranging from leukemia and lung cancer to prostate and pancreatic cancer, as well as treatments for pain management.
